factual
Ipilimumab cures 20% of metastatic melanoma
The anti-CTLA-4 antibody ipilimumab, approved by the FDA in 2011, cures about 20% of people with metastatic melanoma with one or two infusions—a disease in which previously no drug had ever had any effect, median survival was seven months, and fewer than 3% survived to five years; now 20% are alive at 10+ years with a single round of therapy.
factualpending
Speaker
James P. AllisonEvidence Quote
“in melanoma, 20% are alive at 10 years plus. With no other therapy, just one, one round of therapy, you're done.”
Created: 6/13/2026, 12:24:01 AM
Your notes
Loading notes...